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Abstract
We studied longitudinal changes of the levels of anti-amyloid β (anti-Aβ) antibody, amyloid β (Aβ) protein, and
interleukin 8 (IL-8) in cerebrospinal fluid (CSF) of a patient with cerebral amyloid angiopathy-related inflammation
(CAA-ri) in whom steroid treatment resulted in clinical improvement. The diagnosis of CAA-ri was established with
brain biopsy. Levels of anti-Aβ 42 antibody, Aβ 40, Aβ 42 and IL-8 in CSF were measured in the CAA-ri patient at 23
time points in the 8-month clinical course. These CSF samples were divided into 2 groups: those obtained before
(n = 12) and those after (n = 11) oral corticosteroid therapy was started. We compared these levels between CSF
samples obtained before and after therapy. The mean levels of anti-Aβ 42 antibody and IL-8 were significantly
higher in CSF samples of the CAA-ri patient before oral corticosteroid therapy than those after therapy. A positive
correlation was noted between levels of anti-Aβ 42 antibodies and IL-8 in CSF of this patient. There were no
significant differences of mean levels of Aβ 40 and Aβ 42 between CSF samples obtained before and after oral
corticosteroid therapy. It was possible that the autoinflammatory process with anti-Aβ 42 antibodies and IL-8 may
have been involved in the pathogenesis of CAA-ri, and that corticosteroid therapy directly affected levels of anti-Aβ
42 antibody and IL-8. In summary, CAA-ri encephalopathy is a relapsing or progressive disorder and may be
treatable by adequate immunosuppressive therapy. The anti-Aβ 42 antibody in CSF is a useful biological marker for
therapeutic monitoring of CAA-ri.
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Background
Cerebral amyloid angiopathy-related inflammation (CAA-
ri) is characterized by sub-acute confusion, progressive
cognitive decline, seizure or headaches; reversible focal
subcortical and/or cortical T2 hyperintensities on mag-
netic resonance imaging (MRI); and neuropathological
evidence of cerebral amyloid angiopathy (CAA) and asso-
ciated vascular or perivascular inflammation [1-3]. Al-
though the apolipoprotein E ε4/ε4 genotype is strongly
associated with CAA-ri [1], the pathogenesis of CAA-ri is
unknown. Clinical reports have noted a response to
immunosuppressive treatment, suggesting that this syn-
drome may be a treatable form of CAA [4,5]. The syn-
drome may be diagnosed non-invasively, based on a
characteristic combination of clinical and radiographic
features [6], but the only way to confirm the diagnosis is
through brain biopsy. Two previous studies have demon-
strated the presence of anti-amyloid β (anti-Aβ) antibodies
associated with CAA-ri [7,8]. In the present study, we lon-
gitudinally analyzed anti-Aβ antibody, amyloid β (Aβ) pro-
tein and interleukin 8 (IL-8) in cerebrospinal fluid (CSF)
samples of a patient who had the diagnosis of CAA-ri
confirmed with brain biopsy samples.
Case presentation and methods
A 72-year-old woman with an unremarkable past med-
ical history presented with a 5-month history of head-
ache and appetite loss. She developed mild fever and
was admitted to a local hospital. After admission, she
developed a disturbance of consciousness and was trans-
ferred to our hospital. Neurological examination showed
somnolence, meningeal signs and rigidity in both elbow
joints. Laboratory tests showed increased white blood
cell count (17.7 × 109/L; normal range: [3.3 to 7.9] ×
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109/L) and neutrophil cell count (16.0 × 109/L; normal
range; [1.5 to 5.9] × 109/L). The serum C-reactive pro-
tein level was elevated (12.5 mg/dL; normal: <0.20 mg/
dL). Serum antibodies were absent, including antinu-
clear, anti-SS-A, anti-SS-B, anti-DNA, anti-Sm, anti-RNP,
and perinuclear and cytoplasmic anti-neutrophil cytoplas-
mic antibodies. The CSF had 243 cells/mm3 (mononuclear
cells: 98 cells/mm3; polynuclear cells: 145 cells/mm3) and
elevated total protein concentration (133 mg/dL). The im-
munoglobulin G (IgG) index was elevated (0.89; normal:
≤0.73). No CSF oligoclonal IgG bands were detected. Cul-
tures of CSF showed no bacteria, mycobacteria or fungi.
Cryptococcus and aspergillus antigen tests were negative.
Polymerase chain reaction (PCR) was negative for Herpes
simplex virus and Mycobacterium avium complex. The
nested PCR for detection of Mycobacterium tuberculosis
was negative. Bacteria, mycobacteria and fungi were not
detected from CSF or brain tissue using a broad-range
PCR assay targeting the 16S ribosomal RNA gene regions
of bacteria, heat shock protein (hsp65) gene regions of
mycobacterium species, and the internal transcribed
spacer (ITS) regions of fungi. Brain MRI scan (Signa
Excite Xl Twin Speed 1.5 T system, GE Healthcare,
Milwaukee, WI, USA) showed increased signal intensity
on fluid-attenuated inversion recovery (FLAIR) images
in the leptomeninges and sulci (Figure 1).
On admission to our hospital the patient’s conscious-
ness deteriorated further and she required mechanical
respiratory treatment. She was treated with intravenous
antibiotics, antifungal drugs and acyclovir with intraven-
ous methylprednisolone (1,000 mg/day for 3 days with-
out subsequent oral corticosteroids). Her symptoms
transiently improved but her consciousness progressively
deteriorated again, and she required further mechanical
respiratory treatment. At 49 days after admission, a re-
peat MRI scan with T2-weighted and FLAIR images
showed more extensive hyperintensity lesions in the
leptomeninges and sulci, asymmetric subcortical white
matter of the occipital lobes, and hyperintensity lesions
that extended through the white matter (Figure 1).
At 77 days after admission, stereotactic brain biopsy of
the right parietal lobe was performed. Neuropathological
examination revealed advanced CAA. Some of the affected
blood vessels showed inflammatory granulomatous vascu-
litis with perivascular infiltration of lymphocytes, multi-
nucleated giant cells, and reactive astrocytosis in the
surrounding brain parenchyma (Figure 2). Mild, lympho-
cytic infiltration was noted in a piece of the dura mater
sampled. Immunostaining revealed T cell-predominant
perivascular infiltrates and Aβ deposits in the affected
blood vessel walls (Figure 2). The diagnosis of CAA-ri was
made and the patient was treated with intravenous
Figure 1 Axial fluid-attenuated inversion recovery (FLAIR) brain MRI scans of the patient with CAA-ri. (A) At time of admission, there was
increased signal intensity in the leptomeninges and sulci; (B) At 49 days after admission, there were more extensive hyperintensity lesions in the
leptomeninges and sulci, and there was asymmetric subcortical white matter of the occipital lobes; (C) At 195 days after admission, the
hyperintensity lesions extended diffusely through the white matter.
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methylprednisolone (1,000 mg/day for 3 days) followed by
oral corticosteroids. The symptoms gradually improved
and she no longer required mechanical ventilation.
According to the reduction of oral corticosteroid, the total
protein concentration in CSF was elevated again. Then we
added the cyclophosphamide. At 246 days after admission,
she was transferred to another hospital.
Analysis of anti-amyloid β 42 antibody, amyloid β 40,
amyloid β 42 and interleukin 8 levels in cerebrospinal fluid
We measured the levels of anti-Aβ 42 antibody, Aβ 40
and Aβ 42 in CSF at 23 time points in the patient with
CAA-ri during the 8-month clinical course by Enzyme-
Linked Immunosorbent Assay (ELISA). These CSF sam-
ples were divided into 2 groups: those obtained before (0
to 103 days after admission; n = 12) and those after
(≥116 days after admission; n = 11) oral corticosteroid
therapy was started.
The levels of anti-Aβ 42 antibody, Aβ 40, and Aβ 42
were measured in CSF samples of control subjects. These
subjects were 14 age-matched patients with Alzheimer’s
disease and 7 patients with multiple sclerosis who were
randomly selected patients from the Department of Neur-
ology and Geriatrics, Gifu University Graduate School of
Medicine, Japan (Table 1). All patients with multiple
sclerosis met diagnostic criteria for the 2010 revision to
the McDonald criteria [9]. These patients had relapsing
and remitting type, and CSF was sampled during the re-
lapse phase. At the time of CSF sampling, 2 patients with
multiple sclerosis were treated with interferon β1b, 1 pa-
tient was treated with oral prednisolone (5 mg/d), and 1
patient was treated with mizoribine (50 mg/day). All pa-
tients with Alzheimer’s disease met Diagnostic and
Figure 2 Neuropathological findings of the biopsy specimen from the right parietal lobe of the patient with CAA-ri. (A) Multifocal
lymphocytic infiltrates around the leptomeningeal-parenchymal blood vessels, with hyaline thickening and splitting of the walls (double-barrel
formation) (hematoxylin-eosin); (B) The perivascular lymphocytic infiltrates consisting primarily of UCHL1 + T cells (serial section of [A]; UCHL1
immunostain); (C) An affected blood vessel, showing perivascular multinucleated giant cells (arrows) (hematoxylin-eosin); (D) Dense deposition of
Aβ protein in the affected blood vessel wall (serial section of [C]; Aβ immunostain).





No. patients 14 7
Gender, female /
male
7 / 7 5 / 2
Age at evaluation (y) 73 ± 9 42 ± 9
Age at onset (y) 72 ± 9 30 ± 10
Disease duration (y) 1.9 ± 0.7 12 ± 8
Immunomodulatory
therapy†
None Prednisolone, 5 mg/day (1 patient);
interferon β1b, 8 MIU/every other
day (2 patients); mizoribine,
50 mg/day (1 patient)
*Data reported as number or mean ± SD.
†At time of sampling of cerebrospinal fluid.
Kimura et al. Journal of Neuroinflammation 2013, 10:39 Page 3 of 9
http://www.jneuroinflammation.com/content/10/1/39
Statistical Manual of Mental Disorders (DSM)-IV criteria
[10]. No patients with Alzheimer’s disease were treated
with immunosuppressants that could have influenced the
level of anti-Aβ 42 antibodies and IL-8.
We measured the levels of anti-Aβ 42 antibody, Aβ 40
and Aβ 42 in 2 serum samples obtained before oral cor-
ticosteroid therapy in the patient with CAA-ri by ELISA.
We also measured these levels in serum samples of 7 pa-
tients with multiple sclerosis and 10 of 14 patients with
Alzheimer’s disease. The CSF and serum samples of all
subjects were collected and stored at −30°C. Commer-
cially available kits were used for measuring levels of
anti-Aβ 42 antibody (Human anti-Aβ42 ELISA kit, DRG
International, Mountainside, NJ, USA), Aβ 40 and Aβ 42
(Human Aβ 40 and Aβ 42 brain ELISA kits, Millipore,
Billerica, MA, USA). The patient with CAA-ri had poly-
nuclear pleocytosis. Therefore, we also measured the
levels of the neutrophil chemotactic factor IL-8 in CSF,
which is a major mediator of the inflammatory response,
in the CAA-ri patient and control subjects. The IL-8
levels were measured with a commercially available kit
(Human IL-8 ELISA kit, eBioscience, San Diego, CA,
USA). These commercial kits used solid phase ELISA
that was based on the sandwich principle. The level of
anti-Aβ 42 antibody was reported as units, which were
defined commercially from a calibration curve as an in-
dicator of concentration (not as units in enzymatic as-
says that describe turnover rate of substrate under
defined conditions and time). The levels of Aβ40, Aβ42
and IL-8 were reported as concentrations (pg/mL). This
study was approved by the institutional review board of
Gifu University Graduate School of Medicine, Gifu City,
Japan.
Data analysis
The Mann–Whitney test was used to compare the mean
levels of anti-Aβ 42 antibody, Aβ 40, Aβ 42 and IL-8
between CSF samples obtained before and after oral cor-
ticosteroid therapy was started. The Spearman rank cor-
relation was used to assess the correlation between the
anti-Aβ 42 antibody level, IL-8 level, total cell count and
total protein concentration in the CSF samples of the
patient with CAA-ri. Statistical significance was defined
by P ≤0.05.
Results
Comparison of the levels of anti-amyloid β 42 antibody,
amyloid β 40, amyloid β 42 and interleukin 8 in
cerebrospinal fluid samples obtained before and after
oral corticosteroid therapy in the patient with cerebral
amyloid angiopathy-related inflammation
In CSF, the levels of anti-Aβ 42 antibodies varied widely
during the first 4 months of the clinical course (Figure 3).
The mean level of CSF anti-Aβ 42 antibody in this pa-
tient was significantly greater before oral corticosteroid
therapy than after (Figure 4). The mean level of IL-8 also
was significantly greater in CSF samples obtained before































Figure 3 Clinical course and longitudinal changes in levels of anti-Aβ 42 antibody in CSF of the patient with CAA-ri. CPA,
cyclophosphamide; Days: time from admission; mPSL, methylprednisolone; PSL, prednisolone.
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(Figure 5). There were no significant differences of mean
levels of Aβ 40 and Aβ 42 between CSF samples obtained
before and after oral corticosteroid therapy (Figure 6).
Comparison of the levels of anti-amyloid β 42 antibody,
amyloid β 40, amyloid β 42 and interleukin 8 in
cerebrospinal fluid and serum samples between the
patient with cerebral amyloid angiopathy-related
inflammation and control subjects
We evaluated the levels of anti-Aβ 42 antibody, Aβ 40,
Aβ 42 and IL-8 in CSF or serum samples of the CAA-ri
patient and control subjects (Table 2). The mean anti-
Aβ 42 antibody level of CSF samples obtained before oral
corticosteroid therapy was greater in the CAA-ri patient
than control subjects. We detected no increase in the
anti-Aβ 42 antibody levels of serum samples obtained be-
fore oral corticosteroid therapy in the CAA-ri patient
compared with those in control subjects.
The mean Aβ 40 and Aβ 42 levels of the CSF samples
obtained before and after oral corticosteroid therapy,
and all values combined, were lower in the CAA-ri pa-
tient than control subjects. The mean IL-8 level of the
CSF samples obtained before and after oral corticoster-
oid therapy, and all values combined in the CAA-ri pa-
tient, were greater than those in control subjects.
Correlation between the anti-Aβ 42 antibody level, IL-8
level, total cell count and total protein concentration in
the cerebrospinal fluid samples of the patient with
cerebral amyloid angiopathy-related inflammation
We evaluated the correlation between the anti-Aβ 42
antibody level, IL-8 level, total cell count and total pro-
tein concentration in the CSF samples of the patient
with CAA-ri (Figure 7). The CSF total cell count, total
protein concentration and IL-8 level were significantly
correlated with the CSF anti-Aβ 42 antibody level in the
CAA-ri patient. The CSF total cell count also was sig-
nificantly correlated with the CSF IL-8 level.
Discussion
This study showed that the mean level of anti-Aβ 42















Figure 4 Levels of anti-Aβ 42 antibody in CSF of the patient with CAA-ri before and after oral corticosteroid therapy. Mean values are












CSF IL-8 level 
(pg/mL)
*
Figure 5 Levels of IL-8 in CSF of the patient with CAA-ri before
and after oral corticosteroid therapy. Mean values are indicated
by a horizontal line. *P <0.0005.
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greater in CSF samples obtained before starting oral cor-
ticosteroid therapy than those obtained after. After oral
corticosteroid therapy was started in the present CAA-ri
patient, the level of anti-Aβ 42 antibody significantly de-
creased and the clinical symptoms improved. This sup-
ports the concept that anti-Aβ 42 antibodies in CSF may
mediate the autoimmune reaction occurring in CAA-ri,
and that corticosteroids had a therapeutic effect on ele-
vated anti-Aβ 42 antibody in the CSF of the patient with
CAA-ri.
The mean level of anti-Aβ 42 antibody of CSF samples
obtained before oral corticosteroid therapy was greater in
the CAA-ri patient than control subjects. Using CSF/
serum quotient diagrams (Reibergrams), we evaluated
whether this increased level of anti-Aβ 42 antibody of CSF
samples obtained before oral corticosteroid therapy in the
CAA-ri patient was a result of blood–brain barrier damage
or specific intrathecal synthesis [11]. The increased level of
anti-Aβ 42 antibody was not explained by blood–brain bar-
rier damage, but was caused by specific intrathecal synthe-
sis of anti-Aβ antibodies (quotient-anti-Aβ 42 antibody:
54.2 × 10-3; quotient-total IgG: 16.9 × 10-3). This confirms
the findings of recent reports [7,8]. However, the present
study is limited because there was only 1 patient with
CAA-ri. Future studies including a larger number of CAA-
ri patients and control subjects are expected.
The radiographic abnormalities of the present patient
with CAA-ri progressed and did not improve despite
corticosteroid treatment. The beneficial effects of cor-
ticosteroid treatment may vary with the pathological
subtype of CAA-ri. There have been 2 subtypes of CAA-ri
described, including a non-vasculitic form (perivascular
infiltration) and a vasculitic form (transmural granuloma-
tous angiitis) [4]. These pathological forms can occur
together in the same patient [12]. Neuropathological find-


























Figure 6 Levels of Aβ 40 and Aβ 42 in CSF of the patient with CAA-ri before and after oral corticosteroid therapy. Mean values are
indicated by a horizontal line. NS, not significant (P >0.05).
Table 2 Levels of anti-Aβ 42 antibody, Aβ 40, Aβ 42 and IL-8 in CSF or serum of the patient with CAA-ri and control
subjects*
Disease No. samples Anti-Aβ 42 Ab level (U) Aβ 40 (pg/mL) Aβ 42 (pg/mL) IL-8 (pg/mL)
CAA-ri (1 patient) All values CSF 23 1.5 ± 0.9 1030 ± 640 72 ± 8 340 ± 330
2 38 ± 24 1490 ± 327 <0.005 -
Before oral corticosteroids CSF 12 1.9 ± 0.9† 1130 ± 850 78 ± 101 570 ± 290‡
2 38 ± 24 1490 ± 327 <0.005 -
After oral corticosteroids CSF 11 1.4 ± 0.4† 920 ± 290 65 ± 69 80 ± 52‡
Alzheimer’s disease (14 patients) CSF 14 0.8 ± 0.8 4990 ± 2080 540 ± 160 12 ± 46
10 29 ± 19 1330 ± 1040 52.7 ± 120 -
Multiple sclerosis (7 patients) CSF 7 1.2 ± 0.9 4180 ± 2080 770 ± 450 0 ± 0
7 54 ± 22 683 ± 785 <0.005 -
*Data reported as mean ± SD. Ab: Antibody; Aβ: Amyloid β; CAA-ri: Cerebral amyloid angiopathy-related inflammation; CSF: Cerebrospinal fluid; IL-8: Interleukin 8.
†Anti-Aβ 42 Ab level in CSF: difference between levels before and after oral corticosteroids, P ≤0.01.
‡IL-8 level in CSF: difference between levels before and after oral corticosteroids, P ≤0.0005.
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concurrent perivascular infiltration and transmural granu-
lomatous angiitis. In general, patients with transmural
granulomatous angiitis may not benefit as much as pa-
tients with perivascular infiltration by immunosuppressive
therapy. A previous long-term follow-up study showed
that CAA-ri can be a relapsing or progressive disorder [6].
The present CAA-ri patient was treated twice with intra-
venous methylprednisolone pulse therapy. The CSF level
of anti-Aβ 42 antibody was immediately and strongly re-
duced after intravenous methylprednisolone pulse therapy.
However, this antibody level increased within a few weeks
after the first intravenous methylprednisolone pulse ther-
apy that was not followed with oral corticosteroids. The
present study showed that this antibody level was progres-
sively increasing, according to the reduction of oral cor-
ticosteroid. If the CSF level of anti-Aβ 42 antibody
correlates with the ongoing autoimmune process, the pa-
tient’s history suggests that the inflammatory process re-
sumed after the first methylprednisolone pulse, and it may
be advisable to place some CAA-ri patients on immuno-
suppressive treatment. Repeat measurement of this anti-
body level in CSF may help monitor the course of the
disease and efficacy of treatment.
The mean IL-8 level in the present CAA-ri patient was
also significantly greater in CSF samples obtained before
than those after oral corticosteroid therapy (Table 2),
and were greater in the CAA-ri patient than in control
subjects (Table 2). Moreover, a positive correlation was
noted between levels of anti-Aβ 42 antibodies and IL-8
in CSF of the CAA-ri patient (Figure 7). Small heat
shock proteins are associated with Aβ deposits in CAA
and induce a cerebral inflammatory reaction [13]. These
small heat shock proteins induce the production of IL-8
by human leptomeningeal smooth muscle cells and
human brain astrocytes in vitro [13]. Therefore, an
autoinflammatory process with anti-Aβ 42 antibodies
and IL-8 may be involved in the pathogenesis of CAA-ri.
However, caution is advised in the interpretation of these
findings because the results of this study may have been
influenced by an unusual presentation for this patient.
The polynuclear pleocytosis in our patient was atypical
compared with previous reports of CAA-ri with normal
to mild mononuclear pleocytosis [1,3]. A possible ex-
planation for this finding is that the present patient may
have had more severe leptomeningeal vessel inflamma-
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Figure 7 Correlation between the anti-Aβ 42 antibody level, IL-8 level, total cell count and total protein concentration in the CSF
samples of the patient with CAA-ri.
Kimura et al. Journal of Neuroinflammation 2013, 10:39 Page 7 of 9
http://www.jneuroinflammation.com/content/10/1/39
possibility is that the initial presentation was caused by
complications of viral meningoencephalitis. Inflamma-
tory markers including IL-8 may have been high if this
patient had pre-existing viral meningoencephalitis. More
studies are needed to clarify the pathological role of IL-8
in CAA-ri.
The mean levels of Aβ 40 and Aβ 42 in CSF were
lower in the CAA-ri patient than control subjects
(Table 2). This confirms the findings of a previous case
report in which a patient with CAA-ri had a low level of
Aβ 42 level in CSF [7] and other reports that showed
low levels of Aβ 40 and Aβ 42 in CSF of patients with
CAA [14,15]. Previous histological data support the de-
position of Aβ 40 and Aβ 42 proteins in CAA [16]. In
CAA, both Aβ 40 and Aβ 42 may be trapped in the
cerebral vasculature, and deplete these peptides from
CSF. The diagnosis of CAA-ri requires recognition of
CAA [1,17]. Echo gradient imaging and presence of
microbleeds could be used as a useful screening tool in
CAA. We could not perform this imaging in the present
study and could not make the diagnosis of CAA-ri until
the brain biopsy was performed. Echo gradient imaging
can help speed up the diagnostic process and prompt an
earlier biopsy. It is possible that the low level of Aβ 40
and Aβ 42 in CSF could be an alternative screening
marker of CAA and CAA-ri. Further studies are re-
quired to assay levels of Aβ 40 and Aβ 42 in CSF in
more patients with CAA and CAA-ri.
Conclusions
The encephalopathy CAA-ri is treatable by adequate im-
munosuppressive therapy. We demonstrated the possible
therapeutic effect of corticosteroids on elevated anti-Aβ
42 antibody and IL-8 in CSF of the patient with CAA-ri.
It may be helpful to place some CAA-ri patients on im-
munosuppressive therapy, and anti-Aβ 42 antibody in
CSF may be a potentially useful biological marker for
the therapeutic monitoring of CAA-ri.
Consent
Written informed consent was obtained from the next
of kin of the patient for publication of this case report
and any accompanying images. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
Abbreviations
Aβ: Amyloid β; CAA: Cerebral amyloid angiopathy; CAA-ri: Cerebral amyloid
angiopathy-related inflammation; CSF: Cerebrospinal fluid; ELISA: Enzyme-
linked immunosorbent assay; FLAIR: Fluid-attenuated inversion recovery;
IL: Interleukin; MRI: Magnetic resonance imaging.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AK designed this article, analyzed the data and drafted the manuscript. TS,
NY and YH collected the data. MT carried out the immunoassays. HT carried
out the pathological examination. TI helped to analyze the data and draft
the manuscript. All authors read and approved the final manuscript.
Authors’ information
AK, TS, NY, YH and TI are members of the Departments of Neurology and
Geriatrics, Gifu University Graduate School of Medicine, and MT is a member
of the Informative Clinical Medicine, Gifu University Graduate School of
Medicine. HT is a member of the Department of Pathology, Brain Research
Institute, Niigata University.
Author details
1Departments of Neurology and Geriatrics, Gifu University Graduate School
of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan. 2Informative Clinical
Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu
501-1194, Japan. 3Department of Pathology, Brain Research Institute, Niigata
University, 1-757 Asahimachi-dori, Chuo-ku, Niigata City, Japan.
Received: 26 September 2012 Accepted: 27 February 2013
Published: 16 March 2013
References
1. Eng JA, Frosch MP, Choi K, Rebeck GW, Greenberg SM: Clinical
manifestations of cerebral amyloid angiopathy-related inflammation.
Ann Neurol 2004, 55:250–256.
2. Oh U, Gupta R, Krakauer JW, Khandji AG, Chin SS, Elkind MS: Reversible
leukoencephalopathy associated with cerebral amyloid angiopathy.
Neurology 2004, 62:494–497.
3. Scolding NJ, Joseph F, Kirby PA, Mazanti I, Gray F, Mikol J, Ellison D, Hilton
DA, Williams TL, MacKenzie JM, Xuereb JH, Love S: Abeta-related angiitis:
primary angiitis of the central nervous system associated with cerebral
amyloid angiopathy. Brain 2005, 128:500–515.
4. Kloppenborg RP, Richard E, Sprengers ME, Troost D, Eikelenboom P,
Nederkoorn PJ: Steroid responsive encephalopathy in cerebral amyloid
angiopathy: a case report and review of evidence for
immunosuppressive treatment. J Neuroinflammation 2010, 7:18.
5. Sakaguchi H, Ueda A, Kosaka T, Yamashita S, Kimura E, Yamashita T, Maeda
Y, Hirano T, Uchino M: Cerebral amyloid angiopathy-related inflammation
presenting with steroid-responsive higher brain dysfunction: case report
and review of the literature. J Neuroinflammation 2011, 8:116.
6. Kinnecom C, Lev MH, Wendell L, Smith EE, Rosand J, Frosch MP, Greenberg
SM: Course of cerebral amyloid angiopathy-related inflammation.
Neurology 2007, 68:1411–1416.
7. DiFrancesco JC, Brioschi M, Brighina L, Ruffmann C, Saracchi E, Costantino G,
Galimberti G, Conti E, Curtò NA, Marzorati L, Remida P, Tagliavini F,
Savoiardo M, Ferrarese C: Anti-Aβ autoantibodies in the CSF of a patient
with CAA-related inflammation: a case report. Neurology 2011,
76:842–844.
8. Hermann DM, Keyvani K, van de Nes J, Weimar C, Wiltfang J, Nitsch RM,
Szodorai A: Brain-reactive β-amyloid antibodies in primary CNS angiitis
with cerebral amyloid angiopathy. Neurology 2011, 77:503–505.
9. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara
K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor
P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B,
Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2010 revisions to
the McDonald criteria. Ann Neurol 2011, 69:292–302.
10. American Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders. 4th edition. Washington, DC: American Psychiatric Association;
1994.
11. Reiber H: Flow rate of cerebrospinal fluid (CSF)–a concept common to
normal blood-CSF barrier function and to dysfunction in neurological
diseases. J Neurol Sci 1994, 122:189–203.
12. McHugh JC, Ryan AM, Lynch T, Dempsey E, Stack J, Farrell MA, Kelly PJ:
Steroid-responsive recurrent encephalopathy in a patient with cerebral
amyroid angiopathy. Cerebrovasc Dis 2007, 23:66–69.
13. Bruinsma IB, de Jager M, Carrano A, Versleijen AA, Veerhuis R, Boelens W,
Rozemuller AJ, de Waal RM, Verbeek MM: Small heat shock proteins
induce a cerebral inflammatory reaction. J Neurosci 2011, 31:11992–12000.
Kimura et al. Journal of Neuroinflammation 2013, 10:39 Page 8 of 9
http://www.jneuroinflammation.com/content/10/1/39
14. Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME,
Greenberg SM: Cerebrospinal fluid amyloid beta(40) is decreased in
cerebral amyloid angiopathy. Ann Neurol 2009, 66:245–249.
15. Renard D, Castelnovo G, Wacongne A, Le Floch A, Thouvenot E, Mas J,
Gabelle A, Labauge P, Lehmann S: Interest of CSF biomarker analysis in
possible cerebral amyloid angiopathy cases defined by the modified
Boston criteria. J Neurol 2012, 259:2429–2433.
16. Savage MJ, Kawooya JK, Pinsker LR, Emmons TL, Mistretta S, Siman R,
Greenberg BD: Elevated Aβ levels in Alzheimer’s disease brain are
associated with selective accumulation of Aβ42 in parenchymal amyloid
plaques and both Aβ40 and Aβ42 in cerebrovascular deposits. Amyloid
1995, 2:234–240.
17. Knudsen KA, Rosand J, Karluk D, Greenberg SM: Clinical diagnosis of
cerebral amyloid angiopathy: validation of the Boston criteria. Neurology
2001, 56:537–539.
doi:10.1186/1742-2094-10-39
Cite this article as: Kimura et al.: Corticosteroid therapy in a patient with
cerebral amyloid angiopathy-related inflammation. Journal of
Neuroinflammation 2013 10:39.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kimura et al. Journal of Neuroinflammation 2013, 10:39 Page 9 of 9
http://www.jneuroinflammation.com/content/10/1/39
